Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||lung non-small cell carcinoma||not applicable||XL228||Phase I||Actionable||In a Phase I clinical trial, 41% (9/22) of patients with an advanced solid tumor experienced stable disease for at least 12 weeks and a partial response response was reported in one patient with NSCLC when treated with XL228 (J Clin Oncol 28:15s, 2010 (suppl; abstr 3105)).||detail...|
|PubMed Id||Reference Title||Details|
|A phase I study of XL228, a multitargeted protein kinase inhibitor, in patients (pts) with solid tumors or multiple myeloma||Full reference...|